Galectin‐3 promotes CXCR2 to augment the stem‐like property of renal cell carcinoma

Although targeted therapy is usually the first‐line treatment for advanced renal cell carcinoma (RCC), some patients can experience drug resistance. Cancer stem cells are tumour‐initiating cells that play a vital role in drug resistance, metastasis and cancer relapse, while galectins (Gal) participa...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chang‐Shuo, Tang, Shye‐Jye, Lee, Mei‐Hsuan, Chang Wang, Chien‐Chih, Sun, Guang‐Huan, Sun, Kuang‐Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237593/
https://www.ncbi.nlm.nih.gov/pubmed/30246456
http://dx.doi.org/10.1111/jcmm.13860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237593/
https://www.ncbi.nlm.nih.gov/pubmed/30246456
http://dx.doi.org/10.1111/jcmm.13860

Ejemplares similares